Results 71 to 80 of about 8,209 (210)

Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

Drug Design, Development and Therapy, 2021
Meng-Jie Wang,1 Yu-Hang Zhao,2 Chen Fan,3 Ying-Jie Wang,3 Xin-Qi Wang,3 Xiang-Jun Qiu,3 Rui-Le Shen1 1Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan ...
Wang MJ, Zhao YH, Fan C, Wang YJ, Wang XQ, Qiu XJ, Shen RL   +6 more
doaj  

Role of Janus kinase Inhibitors (JAKis) in Autoimmune Disorders: Review [PDF]

JAK inhibitors (JAKis) comprise a crucial therapeutic tool for managing patients with immune-mediated inflammatory disorders. Although often perceived as a uniform class of medications thought to be largely interchangeable, notable variances exist in ...
H. Shehata, Lamia, M. Nasr, Mohamed, Naser, Maged   +2 more
core   +2 more sources

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

The Journal of Dermatology, EarlyView.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei‐ichiro Motegi, Naoko Kanda   +6 more
wiley   +1 more source

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Research & Therapy
Background In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel   +13 more
doaj   +1 more source

Efficacy and safety of upadacitinib in the treatment of recalcitrant vitiligo [PDF]

Background: Vitiligo is an acquired autoimmune disease resulting in depigmented patches of the skin, often leading to a significant psychosocial burden on patients. Building on recent advancements in understanding the immunological mechanisms in vitiligo
Dash, Pranam Swapan, Hasan, M. Kamrul, Khan, M. Alauddin, Khondker, Lubna, Nabila, Noshin, Nasrin, Tanjina, Nath, Pankaj Kanti   +6 more
core   +2 more sources

Budget impact analysis of upadacitinib for the management of moderate-to-severe atopic dermatitis in patients treated with systemic therapies in the United States [PDF]

, 2022
Objective: This study evaluated the budget impact of introducing upadacitinib for patients with uncontrolled moderate-to-severe atopic dermatitis (AD) from a United States (U.S.) private payer perspective.
Alobaid, Haya O
core   +1 more source

Treating to Target in Hidradenitis Suppurativa: Canadian Perspectives

JEADV Clinical Practice, EarlyView.
Wayne Gulliver, Irina Turchin, Tracey Brown‐Maher, Marni Wiseman, Lauren Lam, Jessica Asgarpour, Raed Alhusayen   +6 more
wiley   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis

Diagnostics
Vernal keratoconjunctivitis is a persistent allergic ocular disease predominantly mediated by the T-helper 2 lymphocyte-associated immune response. The standard therapeutic approaches for vernal keratoconjunctivitis include topical corticosteroids and ...
Yoshihito Mima, Eri Tsutsumi, Tsutomu Ohtsuka, Ippei Ebato, Yukihiro Nakata, Taro Kubota, Yuta Norimatsu   +6 more
doaj   +1 more source

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study [PDF]

Introduction: Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial.
Alvarenga, José Miguel, Balato, Anna, Caccavale, Stefano, Carrascosa, Jose-Manuel, Chiricozzi, Andrea, Cruz, Maria João, Daponte, Athina Ioanna, Duarte, Bruno, Farinha, Pedro, Ferrucci, Silvia Mariel, Gkalpakiotis, Spyridon, Gori, Niccolò, Gregoriou, Stamatios, Herranz, Pedro, Kolios, Antonio, Lazaridou, Elizabeth, Marzano, Angelo Valerio, Munera-Campos, Monica, Ortoncelli, Michela, Paiva Lopes, Maria João, Peris, Ketty, Pires Rosa, Gilberto, Prajapati, Vimal H, Prignano, Francesca, Rankin, Brian D, Ribero, Simone, Rompoti, Natalia, Silvi, Gianmarco, Sood, Siddhartha, Torres, Tiago, Yeung, Jensen   +30 more
core   +1 more source